TECH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Techne Corp (TECH) is not a strong buy for a beginner, long-term investor at this time. While the stock has shown recent positive price movement and has some potential catalysts, the overall sentiment from hedge funds, insiders, and Congress is negative, with significant selling activity. Additionally, analysts are cautious, with mixed ratings and lowered price targets. The lack of strong proprietary trading signals and the absence of clear financial growth trends further suggest holding off on investment for now.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is in the neutral zone at 74.653, and moving averages are converging, showing no clear directional trend. Key resistance levels are at R1: 57.33 and R2: 58.979, with the stock price currently near R1, suggesting limited immediate upside potential.
Ananym Capital Management's stake and push for a strategic review could lead to shareholder value improvements. The stock has recently risen 4% following this news.
Hedge funds and insiders are heavily selling the stock, with hedge fund selling increasing by 5004.01% and insider selling by 174.32%. Congress members have also sold shares recently. Analysts have lowered price targets significantly, citing weak Q3 performance and flat Q4 guidance. The stock has declined 8.2% over the past year.
Financial data is unavailable for analysis, but analysts have noted a Q3 organic growth miss and flat Q4 guidance, indicating weak recent performance.
Analyst sentiment is mixed. RBC Capital has an Outperform rating with a $62 target, while Piper Sandler has a Neutral rating with a $65 target. Several firms, including Stifel, Baird, and Evercore ISI, have lowered price targets significantly, with some as low as $49-$50, reflecting cautious sentiment.
